Page 113 - MEMOCiberesp014-ENG

• Pharmacocinetic and biopharmaceutical evaluation of modified drug delivery and therapeutic systems obtained with bio technologic products .
• Nanocarriers for pulmonary administration: the aim of this work line is the design, optimization and characterization of vehicles in the nanometric range that are intended to be administered pulmonary . These systems present many advantages, such as mucoadhesion, biodegradability, no first pass effect hence the possibility to reduce the dose, good tolerability, deep lung deposition of the drug and sus- tained release of the API thus longer dosing interval . These systems are applied for the nanoformula- tion of DNA, peptide, antineoplasics and antibiotics .
Most relevant scientific articles
• Puras g., Mashal M., zarate J., agirre M., oJeDa e., griJalVo s. et al . A novel cationic niosome formula- tion for gene delivery to the retina . Journal of Controlled Release . 2014;174(1):27-36 .
• gainza g., Pastor M., aguirre J.J., Villullas s., PeDraz J.l., hernanDez r.M. et al . A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice . Journal of Controlled Release . 2014;185(1):51-61 .
• Pastor M., Moreno-sastre M., esquisaBel a., sans e., Vinas M., BaChiller D. et al . Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis . International Journal of Pharmaceutics . 2014;477(1-2):485-494 .
• herran e., requeJo C., ruiz-ortega J.a., aristieta a., igartua M., BengoetXea h. et al . Increased antipar- kinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease . International Journal of Nanomedicine . 2014;9(1):2677-2687 .
• Del Burgo l.s., hernÁnDez r.M., oriVe g., PeDraz J.l. Nanotherapeutic approaches for brain cancer ma- nagement . Nanomedicine: Nanotechnology, Biology, and Medicine . 2014;10(5):905-919 .
Highlights
Institution: Universidad del País Vasco Contact: Facultad de Farmacia de Vitoria · Po Universidad, 7 . 1006 Vitoria · Tel . (+34) 945 013 091 E-mail: joseluis .pedraz@ehu .es · Website: http://www .ehu .es/en/web/nanobiocel/home
During 2014, several relevant facts had been achieved regarding scientific results and also with respect to contracts with companies .
As a result of team work we got two patents with Praxis, a spanish pharmaceutical company: “lipid nanoparticles of tobramicine” and biodegradable biobnanoparticles to release GSE24-2 peptides:
procedure of extraction and usage . Regarding national projects: we got a “Reto de Investigación 2013” project from the Ministery of Economy and Competitiveness: nanoencasulated neurotrophic factors and gene therapy to treatment of neurodegenerative diseasesusing less invasive routes: NANOTEG .The duration of this project is from 2014 to 2018 and has a grant of 200 .000 euros . We got also a “Reto de Colaboración“ project with Sylentis a RNAi therapeutics company jointly with two CIBER BBN groups: NN-UMH from Elche led by Eduardo Fernandez and GQNA-CSIS led by Rammon Eritja from Barcelona . The ttle of the project is: new treatments to combat degenerative retina illnesses .
Another aspect to highlight, during 2014, is the total income the group obtained through different contracts tallied to 741 .069 euros .
www .ciber-bbn .es 113